Need to improve clinical trials in rare neurodegenerative disorders

Annali dell'Istituto Superiore di Sanita

Volumn 47, Issue 1, 2011, Pages 55-59

  Puopolo, Maria ^a   Pocchiari, Maurizio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Clinical trials; Neurodegenerative diseases

Indexed keywords

ANIMAL; ARTICLE; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DRUG SCREENING; HEALTH SERVICE; HUMAN; METHODOLOGY; PATIENT SELECTION; RARE DISEASE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; NEURODEGENERATIVE DISEASES; PATIENT SELECTION; RARE DISEASES; RESEARCH DESIGN;

EID: 79953114857     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: 10.4415/ANN-11-01-12     Document Type: Article

References (33)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rate? Nat Rev Drug Discov 2004;3:711-5. (Pubitemid 39173511)
2. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91. (Pubitemid 24065791)
3. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;2:CD001447.
4. Sorenson E. What is next in ALS clinical trials? Neurology 2007;69:719-20. (Pubitemid 47300927)
5. Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994;35:513-29. (Pubitemid 24153834)
6. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-5. (Pubitemid 26102546)
7. Ward HJ, Everington D, Cousens SN, Smith-Bathgate B, Leitch M, Cooper S, Heath C, Knight RS, Smith PG, Will RG. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol 2006;59:111-20. (Pubitemid 43042877)
8. Coste J, Prowse C, Eglin R, Fang C. A report on transmissible spongiform encephalopathies and transfusion safety. Vox Sang 2009;96:284-91.
9. Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006;67:389-93. (Pubitemid 44214958)
10. Manson JC, Jamieson E, Baybutt H, Tuzi NL, Barron R, McConnell I, Somerville R, Ironside J, Will R, Sy MS, Melton DW, Hope J, Bostock C. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J 1999;18:6855-64.
11. Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci USA 2010;107:12005-10.
12. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 2010;16:1210-4.
13. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR. Can animal models of disease reliably inform human studies? PLoS Med 2010;7:e1000245.
14. Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, Thomas D, Walker S, Webb T, Wroe S, Darbyshire J. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009;8:334-44.
15. Aggarwal S, CudKowicz M. ALS Drug development: Reflection from the past and a way forward. Neurotherapeutics 2008;5:516-27.
16. Moore DH, Miller R. Improving efficiency of ALS clinical trials using lead-in designs. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(Suppl. 1):57-60. (Pubitemid 39406535)
17. Swash M. Learning from failed trials in ALS. Lancet Neurol 2007;6:1034-5. (Pubitemid 350116692)
18. Swash M. We have a problem: why have ALS trials been negative? Amyotroph Lateral Scler 2007;8:259. (Pubitemid 47543088)
19. Aggarwal S, McDermott MP, Miller RG. Toward more efficient clinical trials for ALS. Amyotroph Lateral Scler 2010; 11:259-65.
20. Levin B. Statistical issues. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(Suppl. 1):43-5. (Pubitemid 39406530)
21. Mitsumoto H. Gordon P, Kaufmann P, Gooch C, Przedborski S, Rowland LP. Randomised control trials in ALS: lesson learned. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(Suppl. 1):8-13. (Pubitemid 39406521)
22. Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JL. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006;66:660-3. (Pubitemid 43739818)
23. Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, Macarthur RB, Montes J, Bednarz K, Florence J, Rowin J, Boylan K, Mozaffar T, Tandan R, Mitsumoto H, Kelvin EA, Chapin J, Bedlack R, Rivner M, McCluskey LF, Pestronk A, Graves M, Sorenson EJ, Barohn RJ, Belsh JM, Lou JS, Levine T, Saperstein D, Miller RG, Scelsa SN; Combination Drug Selection Trial Study Group. Combination Drug Selection Trial Study Group. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 2008;9:212-22.
24. Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kieburtz K, Shoulson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG. Toward more efficient clinical trials for ALS. Amyotroph Lateral Scler 2010;11:259-65.
25. Shoenfeld DA, Cudkowicz M. Design of Phase II ALS clinical trials. Amyotroph Lateral Scler 2008;9:16-23. (Pubitemid 351260368)
26. Committee for Medicinal Products for Human Use (CHMP). CHMP reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design, 2007. Available from: www.emea.europa.eu/pdfs/human/ewp/ 245902enadopted.pdf.
27. US Food and Drug Administration (FDA). Guidance for industry. Adaptive design clinical trials for drugs and biologics. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM201790.pdf.
28. Quinlan J, Gaydos B, Maca J, Krams M. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials 2010;7:167-73.
29. Rosenberger WF, Lachin JM. The use of response-adaptive designs in clinical trials. Control Clin Trials 1993;14:471-84. (Pubitemid 24003705)
30. Morgan CC, Coad SD. A comparison of adaptive allocation rules for group-sequential binary response clinical trials. Stat Med 2007;26:1937-54. (Pubitemid 46534085)
31. Puopolo M, Pocchiari M, Petrini C. Clinical trials and methodological problems in prion diseases. Lancet Neurol 2009;8:782.
32. Pocchiari M, Ladogana A, Graziano S, Puopolo M. Creutzfeldt-Jakob disease: hopes for therapy. Eur J Neurol 2008;15:435-6. (Pubitemid 351499198)
33. Ledford H. Clinical drug tests adapted for speed. Nature 2010;464:1258.